The Siberian Scientific Medical Journal
 
 
№ 3 / 2017 / 11-16

EXPERIMENTAL SUBSTANTIATION OF APPLICATION OF PEGYLATED INTERFERON α-2b ORAL FORMULATION FOR THERAPY OF ENTEROVIRAL INFECTION

Author Affiliations

Abstract

The purpose of the work is the study of the antiviral activity and some pharmacokinetic parameters of oral formulation of pegylated interferon α-2b (PEG-IFN α-2b) obtained by technology of electron-beam synthesis. Material and Methods. The antiviral activity of PEG-IFN α-2b against Coxsackie virus was studied in RD cells culture. To study the pharmacokinetics we used FITC-labeled PEG-IFN α-2b. Results and Discussion. PEG-IFN α-2b has a specific activity comparable to the original interferon. Bioavailability of PEG-IFN α-2b is 29.68% in intragastric administration. The drug is detected in the intestinal tissue in a sufficiently high concentration.

Key words

immobilization, immobilized interferon α-2b, interferon α-2b, nanotechnology, pegylation, enteroviral infection
References
About Authors (Correspondence):

Kinsht D.N. – candidate of medical sciences, associate professor of the chair for pharmacology, clinical pharmacology and evidentiary medicine, е-mail: kinsht@scpb.ru

Full Text

Received: 28/06/2017
Accepted: 28/06/2017